While oncology players usually study the biology of the 97% of patients who die from the most lethal Cancers, we focus on the rare miraculous 3% of patients who do survive: the Outliers.

We want every patient to become an Outlier.

Cancer is the disease of the century.

It is the 2nd mortality cause in the world.

Cancer cases are growing more than 2.5 times faster than human demographic growth, according to the International Agency for Research on Cancer.

Cure 51 focuses on patients who have survived some of the most lethal Cancers including Metastatic Pancreatic Ductal Adenocarcinoma, Glioblastoma and Extensive stage Small Cell Lung Cancer.​

Patients with Cancer who respond exceptionally well to therapy may have molecular changes in their tumors that explain their response. A comprehensive analysis of this group that identified these changes may help to contribute to the development of potential new treatments.

Our proprietary Discovery Platform will be the hub for organizing, analyzing and discovering novel therapeutic targets.​

We are building a unique clinical and multi-omics database of Outliers across all continents.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

We develop precision medicine tools in order to deliver actionable insights for pharmaceutical companies.

We are a tech-bio company co-created with leading international oncology centers and researchers.

Our scientific committee includes world renowned scientists

Our scientific approach has already been validated by academia.

Landmark initiatives have recently emerged in the field of Outliers and paved the way to their analysis at scale with our company.

Cure51’s protocol and clinical trial, ROSALIND, are led by a team of investigators that have contributed to the field.